Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolizatio
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000053279
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
exclusion criterion 1. Child-Pugh C patients: 2. Patients with esophageal varices that may cause bleeding 3. Patients with gastrointestinal bleeding within 1 month 4. Patients who are pregnant, may be pregnant, or are breastfeeding 5. Patients with severe hypersensitivity to the components of this drug 6. Patients with severe heart failure or renal failure 7. Patients with malignant tumors other than hepatocellular carcinoma 8. Other patients unsuitable as subjects by the research director
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparing the amount of change in VEGF levels before and after Transarterial Chemoembolization for each systemic drug therapy
- Secondary Outcome Measures
Name Time Method